Intelligent Bio Solutions (INBS) reported fiscal 2026 revenue of $4.22 million, up 38% from $3.05 million in fiscal 2025. The company recorded a net loss of $12.47 million, compared with a $10.60 million net loss a year earlier.
Full-year gross profit increased 64% to $2.05 million, while gross margin expanded to 48.63% from 40.85%. The company said its FDA 510(k) submission remains on track for the second half of calendar 2026.
- Reader installed base increased 22% to 1,886 units as of June 30, 2026.
- Consumable cartridge volume rose 35% to 106,500 units.
- Active customers totaled 502 as of June 30, 2026.
- Basic and diluted net loss per share was $8.44, following a 1-for-10 reverse stock split.
- INBS completed clinical data collection for its FDA 510(k) clinical study program.
$INBS Hedge Fund Activity
We have seen 4 institutional investors add shares of $INBS stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. removed 37,956 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $87,109
- ARMISTICE CAPITAL, LLC added 11,397 shares (+8.8%) to their portfolio in Q2 2026, for an estimated $26,156
- GEODE CAPITAL MANAGEMENT, LLC removed 7,769 shares (-27.2%) from their portfolio in Q2 2026, for an estimated $17,829
- UBS GROUP AG added 5,363 shares (+1441.7%) to their portfolio in Q2 2026, for an estimated $12,308
- TOWER RESEARCH CAPITAL LLC (TRC) added 2,030 shares (+162.4%) to their portfolio in Q2 2026, for an estimated $4,658
- CURIO WEALTH, LLC removed 200 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $459
- BARCLAYS PLC added 142 shares (+inf%) to their portfolio in Q2 2026, for an estimated $325
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
